Skip to main content
HCPCS J3315 · Level II · Part B drug

J3315: triptorelin pamoate (Trelstar), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3315

Billing unit
3.75 MG
Triptorelin pamoate
ASP payment limit
$467.059
October 2026; +0.2% vs July 2026
Practitioner MUE
6
MAI 3
OPPS status
SI K
APC 9122
NCCI exposure
no PTP pairs
Coverage articles
2
9 states

TL;DR

HCPCS J3315 is the Level II code for Injection, triptorelin pamoate, 3.75 mg, billed per 3.75 MG. The Medicare Part B ASP payment limit for October 2026 is $467.059 per billing unit, up 0.2% from July 2026. The practitioner MUE allows up to 6 units per date of service (MAI 3), so a full 6-unit day is $2,802.35 at the current limit. Under OPPS it carries status indicator K in APC 9122. J3315 is billed in units of 3.75 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 3 NDCs to it, sold as Trelstar by Verity Pharmaceuticals Inc. 2 Medicare coverage articles list the code across 9 states, including A52453.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3315 at $467.059 per 3.75 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $466.365 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3315
QuarterPayment limitPerCoinsurance
October 2026$467.0593.75 MG20%
July 2026$466.3653.75 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 3 NDCs from 1 labeler to J3315. Report the NDC in the claim's drug segment and bill the number of J3315 units that equals the quantity administered divided by 3.75 MG; the last column gives units per full package.

NDCs that crosswalk to J3315
NDCDrug nameLabelerPackage sizeBilling units / package
74676-5902-01TrelstarVerity Pharmaceuticals Inc.1 × 11
74676-5904-01TrelstarVerity Pharmaceuticals Inc.1 × 13
74676-5906-01TrelstarVerity Pharmaceuticals Inc.1 × 16

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J3315. For practitioners the limit is 6 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J3315 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services63 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital63 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J3315 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3315 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3315 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3315 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

2 current Medicare Administrative Contractor articles list J3315 in their HCPCS tables, covering 9 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J3315
ArticleTitleContractor(s)StatesRelated LCD
A52453Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) AnalogsWellpoint FederalCT IL MN NY WIL33394
A59160Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) AnalogsPalmetto GBANC SC VA WVL39387

Diagnoses Medicare contractors cover for J3315

2 billing and coding articles attach a covered diagnosis list to J3315: 25 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J3315
ICD-10-CMDescription (FY2027)Articles covering
C61Malignant neoplasm of prostate2 of 2
Z85.46Personal history of malignant neoplasm of prostate2 of 2
D07.5Carcinoma in situ of prostate1 of 2
D25.0Submucous leiomyoma of uterus1 of 2
D25.1Intramural leiomyoma of uterus1 of 2
D25.2Subserosal leiomyoma of uterus1 of 2
N60.11Diffuse cystic mastopathy of right breast1 of 2
N60.12Diffuse cystic mastopathy of left breast1 of 2
N80.01Superficial endometriosis of the uterus1 of 2
N80.02Deep endometriosis of the uterus1 of 2
N80.03Adenomyosis of the uterus1 of 2
N85.01Benign endometrial hyperplasia1 of 2
C77.2Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes1 of 2
C77.4Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes1 of 2
C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions1 of 2
10 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J3315 are counted here: a group whose instructions name J3315, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J3315, by article
ArticleContractorGroups that applyCovered codes for J3315Full list
A52453Wellpoint Federalgroups 2 and 3 apply to J331525On LCD L33394
A59160Palmetto GBAgroup 5 applies to J33152On LCD L39387

Local coverage policies that list J3315

2 active Local Coverage Determinations list J3315 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3315 carries status indicator K and is assigned to APC 9122, with a published national unadjusted payment of $467.059. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3315 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $467.06 per 3.75 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J3315 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3315

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3315

What does HCPCS code J3315 describe?

J3315 is defined by CMS as "Injection, triptorelin pamoate, 3.75 mg". Each billing unit represents 3.75 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3315 a CPT code?

No. J3315 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as triptorelin pamoate (Trelstar); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3315 reports the drug itself in 3.75 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3315 in October 2026?

The ASP-based payment limit is $467.059 per 3.75 MG, with 20% beneficiary coinsurance. The July 2026 limit was $466.365. Commercial payers use their own fee schedules.

How many units of J3315 can be billed per day?

The practitioner Medically Unlikely Edit is 6 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J3315?

The October 2026 ASP crosswalk lists 3 NDCs from 1 labeler: Trelstar (Verity Pharmaceuticals Inc.). For example NDC 74676-5902-01 (package size 1) equals 1 billing unit of J3315.

Does J3315 have NCCI bundling edits?

No active practitioner PTP pairs list J3315 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J3315?

2 current Billing and Coding Articles in the Medicare Coverage Database list J3315, covering 9 states: A52453 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs); A59160 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs).

What diagnosis codes support J3315?

2 Medicare billing and coding articles list 25 covered ICD-10-CM codes for J3315 between them, for example C61 (Malignant neoplasm of prostate); Z85.46 (Personal history of malignant neoplasm of prostate); D07.5 (Carcinoma in situ of prostate); D25.0 (Submucous leiomyoma of uterus); D25.1 (Intramural leiomyoma of uterus). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.